- Dashcam video of Lowe's truck crash going viral (7/26/17)1
- Former Sikeston DPS director denies knowing about allegations against detective (7/20/17)1
- Chaffee City Council fires officer facing criminal charge (7/23/17)1
- Wreck flips Lowe's truck in Cape (7/25/17)4
- 49-year-old homicide victim found in Cape (7/20/17)
- Major Case Squad seeks woman in connection with homicide investigation (7/26/17)
- At least one Perryville cop disciplined for misconduct (7/20/17)1
- More details emerge in Perryville police-misconduct case (7/21/17)
- Cape homicide victim identified (7/21/17)
- Painted-rock hunts catch fire in Cape area (7/20/17)
Ginkgo fails to prevent Alzheimer's in large study
CHICAGO -- The dietary supplement ginkgo, long promoted as an aid to memory, didn't help prevent dementia and Alzheimer's disease in the longest and largest test of the extract in older Americans.
"We don't think it has a future as a powerful anti-dementia drug," said Dr. Steven DeKosky of the University of Virginia School of Medicine, who led the federally funded study.
Extracts from ginkgo tree leaves have antioxidant and anti-inflammatory effects, but earlier research on ginkgo and memory showed mixed results. Annual U.S. sales of the supplement reached $107 million in 2007, according to Nutrition Business Journal estimates.
Similar dementia rates
For the new study, appearing in today's Journal of the American Medical Association, researchers recruited more than 3,000 people, ages 75 and older, from voter and mailing lists in Maryland, Pennsylvania, California and North Carolina.
Half were randomly assigned to take 120 milligrams of ginkgo biloba twice a day, a typical dose taken by people who think it may help memory. The others took identical dummy pills.
Participants were screened for dementia every six months. After six years, dementia had been diagnosed at a similar rate in both groups; 277 in the ginkgo group and 246 in the group taking the dummy tablets. When the researchers looked only at Alzheimer's disease, that rate too was similar.
At the start, some people showed mild difficulties with thinking; ginkgo didn't work to prevent dementia in those people either.
Ginkgo safe for many
Ginkgo appears relatively safe, DeKosky said. There was no difference in the rate of adverse events such as heart attacks and gastrointestinal bleeding between the groups. There were 16 strokes from bleeding in the brain in the ginkgo group versus eight in the placebo group, a difference that wasn't statistically significant because the number of strokes was too small.
People on the blood thinner warfarin shouldn't take ginkgo because of the risk of increased bleeding.
Proponents claim ginkgo protects the brain by preventing the buildup of an Alzheimer's-related protein or by preventing cell-damaging oxidative stress.
Would ginkgo work better to prevent dementia if people started taking it earlier, say, in middle age? The study didn't look at that, DeKosky said, adding that following people for 25 years from middle age to old age would be expensive research. The study also didn't test whether ginkgo improves thinking and memory in the short term.
"It would have been terrific if this worked. It's inexpensive, available and relatively safe," said Paul Solomon, professor of neuroscience at Williams College in Williamstown, Mass., who wasn't involved in the new study but has studied ginkgo.
"Now with this kind of evidence, you can confidently tell people it didn't show benefit in more than 3,000 people in six years of research," Solomon said.
There may still be a role for ginkgo in treating, rather than preventing, Alzheimer's disease, said Michael McGuffin, president of the American Herbal Products Association, a trade association.
Some previous ginkgo trials have shown no benefit in Alzheimer's symptom treatment, while others have found it comparable to prescription drugs such as Aricept, also known as donepezil.
A four-month supply of ginkgo can cost less than $10. But not all brands contain what their labels claim. ConsumerLab.com, which tests the ingredients in supplements, reported Tuesday that of seven ginkgo products it reviewed, five failed to pass its tests. An eighth ginkgo product also passed the group's test in a voluntary certification program.
The dementia study was funded by a grant from the National Institutes of Health's National Center for Complementary and Alternative Medicine, which is undertaking large, scientific tests of a number of commonly used dietary supplements. The agency said it's the largest-ever randomized trial of a botanical medicine. There have been larger studies of vitamins and minerals.
DeKosky reported receiving grants from and acting as a consultant for several drug companies, including some that make dementia drugs. Schwabe Pharmaceuticals of Karlsruhe, Germany, provided the ginkgo tablets and identical placebos.
On the Net:
Ginkgo fact sheet: http://nccam.nih.gov/health/ginkgo